Mineralys Therapeutics (MLYS) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Mineralys Therapeutics (MLYS) right now is Lorundrostat FDA decision: The single largest driver is the FDA review of lorundrostat, with a PDUFA target date of December 22, 2026. Product revenue (TTM) is ~$0 (pre-commercial). If that keeps playing out, the setup is favourable; the risk to it is the dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe. No one can predict where MLYS trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Mineralys Therapeutics (MLYS) higher?
1. Lorundrostat FDA decision
The single largest driver is the FDA review of lorundrostat, with a PDUFA target date of December 22, 2026. An approval would move Mineralys from clinical-stage to a commercial-stage company with a first-in-class-tier aldosterone synthase inhibitor. The decision is the defining catalyst for the stock over the coming year.
2. Large uncontrolled-hypertension market
Uncontrolled and resistant hypertension affects a very large patient population that remains poorly served by existing generic therapies. Lorundrostat targets aldosterone, a hormone implicated in blood pressure that current standard regimens do not directly address. If approved and adopted, even modest penetration of this market could support substantial revenue.
3. Pipeline expansion into CKD and OSA
Beyond core hypertension, Mineralys is studying lorundrostat in chronic kidney disease and obstructive sleep apnea, conditions where aldosterone dysregulation plays a role. Positive data in these adjacent indications could broaden the drug's addressable market and lengthen its commercial runway well beyond an initial hypertension label.
4. Balance sheet and launch readiness
With roughly $646 million in cash as of March 2026 and runway guided into 2028, Mineralys has capital to fund a potential launch and continued trials without immediate financing pressure. The company has also raised additional equity in 2026, adding cushion but modestly diluting existing holders.
What could weigh on MLYS?
The dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe. Competition is real, most notably AstraZeneca's baxdrostat, another late-stage aldosterone synthase inhibitor with strong Phase 3 data, plus other emerging candidates. As a pre-revenue biotech, Mineralys burns cash and has raised equity, creating dilution risk. Even with approval, commercial execution (payer coverage, physician adoption, and pricing in a market full of cheap generics) is uncertain. The stock is volatile and highly sensitive to trial readouts and regulatory news.
Where MLYS trades today
A forecast starts from where the stock actually is. These are MLYS's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for MLYS as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a MLYS forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the MLYS guide and whether MLYS is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the MLYS outlook
The bottom line: what is driving Mineralys Therapeutics (MLYS) is Lorundrostat FDA decision, with product revenue (ttm) at ~$0 (pre-commercial). If that keeps playing out the setup is favourable; the risk is the dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe. No one can predict the price, so treat any MLYS forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around MLYS with Walnut
Use Mineralys Therapeutics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Mineralys Therapeutics (MLYS)?
+
No one can reliably predict where MLYS will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Mineralys Therapeutics higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive MLYS higher?
+
The main growth drivers are Lorundrostat FDA decision; Large uncontrolled-hypertension market; Pipeline expansion into CKD and OSA. Whether they play out is the real question, not a guaranteed path.
What are the risks to MLYS?
+
The dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe. Competition is real, most notably AstraZeneca's baxdrostat, another late-stage aldosterone synthase inhibitor with strong Phase 3 data, plus other emerging candidates. As a pre-revenue biotech, Mineralys burns cash and has raised equity, creating dilution risk. Even with approval, commercial execution (payer coverage, physician adoption, and pricing in a market full of cheap generics) is uncertain. The stock is volatile and highly sensitive to trial readouts and regulatory news.
Will MLYS stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Mineralys Therapeutics's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is MLYS a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the MLYS "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.